Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and Docetaxel in Locally Advanced Breast Cancer
NCT00027885Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Nov 2001
- Primary completion
- Dec 2005
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in breast cancer (2 arms), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Reduction of microvessel density and induction of apoptosis of endothelial and tumor cells at 17 weeks. Started Nov 2001; status: completed.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00027885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027885.